What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis

Author:

Heyckendorf Jan123,Andres Sönke4,Köser Claudio U.5ORCID,Olaru Ioana D.12ORCID,Schön Thomas67,Sturegård Erik8,Beckert Patrick29,Schleusener Viola9,Kohl Thomas A.29,Hillemann Doris4,Moradigaravand Danesh10,Parkhill Julian10ORCID,Peacock Sharon J.51011,Niemann Stefan29,Lange Christoph1231213ORCID,Merker Matthias29

Affiliation:

1. Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany

2. German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel, Borstel, Germany

3. International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany

4. Division of Mycobacteriology (National Tuberculosis Reference Laboratory), Research Center Borstel, Borstel, Germany

5. Department of Genetics, University of Cambridge, Cambridge, United Kingdom

6. Department of Infectious Diseases and Clinical Microbiology, Kalmar County Hospital, Kalmar, Sweden

7. Department of Clinical and Experimental Medicine, Division of Medical Microbiology, Linköping University, Linköping, Sweden

8. Clinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden

9. Division of Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany

10. Wellcome Trust Sanger Institute, Hinxton, United Kingdom

11. London School of Hygiene & Tropical Medicine, London, United Kingdom

12. Department of Medicine, Karolinska Institute, Stockholm, Sweden

13. Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia

Abstract

ABSTRACT Rapid and accurate drug susceptibility testing (DST) is essential for the treatment of multi- and extensively drug-resistant tuberculosis (M/XDR-TB). We compared the utility of genotypic DST assays with phenotypic DST (pDST) using Bactec 960 MGIT or Löwenstein-Jensen to construct M/XDR-TB treatment regimens for a cohort of 25 consecutive M/XDR-TB patients and 15 possible anti-TB drugs. Genotypic DST results from Cepheid GeneXpert MTB/RIF (Xpert) and line probe assays (LPAs; Hain GenoType MTBDR plus 2.0 and MTBDR sl 2.0) and whole-genome sequencing (WGS) were translated into individual algorithm-derived treatment regimens for each patient. We further analyzed if discrepancies between the various methods were due to flaws in the genotypic or phenotypic test using MIC results. Compared with pDST, the average agreement in the number of drugs prescribed in genotypic regimens ranged from just 49% (95% confidence interval [CI], 39 to 59%) for Xpert and 63% (95% CI, 56 to 70%) for LPAs to 93% (95% CI, 88 to 98%) for WGS. Only the WGS regimens did not contain any drugs to which pDST showed resistance. Importantly, MIC testing revealed that pDST likely underestimated the true rate of resistance for key drugs (rifampin, levofloxacin, moxifloxacin, and kanamycin) because critical concentrations (CCs) were too high. WGS can be used to rule in resistance even in M/XDR strains with complex resistance patterns, but pDST for some drugs is still needed to confirm susceptibility and construct the final regimens. Some CCs for pDST need to be reexamined to avoid systematic false-susceptible results in low-level resistant isolates.

Funder

German Center for Infection Research

Health Innovation Challenge Fund

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference61 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3